BioXcel adds Pfizer, Merck to pancreatic cancer therapy collaboration
Category: #health  By Mateen Dalal  Date: 2019-03-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

BioXcel adds Pfizer, Merck to pancreatic cancer therapy collaboration

BioXcel Therapeutics, Inc. has made an announcement confirming the addition of Germany-based Merck KGaA as well as Pfizer Inc. to its clinical collaboration with Nektar Therapeutics for evaluating an innovative triple combination treatment for pancreatic cancer.

Reportedly, the collaboration would now include avelumab, which is co-developed and co-commercialized by Pfizer and Merck KGaA, BXCL701 developed by BioXcel and NKTR-214 which is developed by Nektar.

As part of the collaboration, BioXcel said it would be responsible for the initiation and management of the clinical program and Nektar would be supplying NKTR-214, with Merck KGaA and Pfizer supplying avelumab. All the development costs would equally be shared between BioXcel and Nektar.

The company has informed that primary objectives of the trial would be to evaluate the efficacy and safety of the triple combination consisting of avelumab, BXCL701 and NKTR-214 for treating patients suffering from pancreatic cancer. In addition, evaluation will also be done for correlative immune activation markets in tumor tissue and blood.

CEO of BioXcel Therapeutics, Mr. Vimal Mehta stated that the company believes expansion of this clinical collaboration offers certain evidence of the industry’s interest towards BXCL701. He mentioned that working closely with Pfizer and Merck KGaA along with Nektar Therapeutics, BioXcel would be leveraging their regulatory and clinical expertise as it looks to establish a development plan for the triple combination therapy in pancreatic cancer patients.

Jonathan Zalevsky, Nektar Therapeutics’ Chief Scientific Officer, said it is vital to target multiple dimensions of the immune system while also addressing the multi-faceted etiologies associated with cell cancer growth in pancreatic cancer and other hard-to-treat tumors.

Zalevsky further added that the experimental regimen of the triple combination of BXCL701, NKTR-214 and avelumab has been designed to leverage multiple action mechanisms for fighting pancreatic cancer better, while generating potentially long-term immunity to cancer.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Facebook and Instagram owner Meta to lay off 10,000 jobs to cut costs
Facebook and Instagram owner Meta to lay off 10,000 jobs to cut costs
By Mateen Dalal

Meta, the leading American technology company and the owner of social media platforms Facebook and Instagram, has reportedly announced its plans to lay off around 10,000 employees. Apparently, this is going to be the second round of significant la...

Heathrow to lower passenger charges to feed through to the ticket prices
Heathrow to lower passenger charges to feed through to the ticket prices
By Mateen Dalal

Heathrow Airport, the U.K.’s leading international airport, has reportedly been advised to reduce passenger costs for airlines next year, as they would have an impact on ticket pricing. The Civil Aviation Authority (CAA) determined that lowe...

Amazon signs deal with mortgage lender Better.com to give employee benefits
Amazon signs deal with mortgage lender Better.com to give employee benefits
By Mateen Dalal

Amazon, the U.S.-based e-commerce giant, has reportedly inked a deal with struggling mortgage lender, Better.com to provide better perks to employees. For the unversed, Better.com is introducing Equity Unlocker, a product that enables staff member...